Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

Video

In Partnership With:

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

Cindy Varga, MD, hematologist, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

The phase 1/2 TAK-573-1501 trial (NCT03215030) is currently evaluating the safety and efficacy of modakafusp alfa (TAK-573), an anti-CD38 monoclonal antibody fused with 2 interferon molecules. The immunosuppressant reduces off-target toxicities for patients who have previously undergone anti-CD38 therapy.

Additionally, a phase 2 study of magrolimab (NCT04892446), a monoclonal antibody targeting CD47, aims to evaluate its efficacy of in combination with other anticancer therapies in this patient population. Magrolimab disrupts the anti-phagotic signal overexpressed in tumor cells, allowing them to be identified and engulfed by macrophages in the immune system.

Researchers are also investigating methods of overcoming resistance to carfilzomib (Kyprolis) through the investigator-initiated trial of JAK/STAT inhibitor ruxolitinib (Jakafi) in the phase 1/2 CARJAK study (NCT03773107).

All of these trials are open to patients who have seen several lines of therapy and are looking for expanded options, Varga concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Related Content
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
FDA

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024
Article
The FDA has approved idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

April 5th 2024
Article